KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Research & Development (2016 - 2025)

Nektar Therapeutics has reported Research & Development over the past 16 years, most recently at $29.7 million for Q4 2025.

  • Quarterly results put Research & Development at $29.7 million for Q4 2025, up 3.36% from a year ago — trailing twelve months through Dec 2025 was $117.3 million (down 2.96% YoY), and the annual figure for FY2025 was $117.3 million, down 2.96%.
  • Research & Development for Q4 2025 was $29.7 million at Nektar Therapeutics, up from $27.3 million in the prior quarter.
  • Over the last five years, Research & Development for NKTR hit a ceiling of $107.3 million in Q1 2022 and a floor of $24.1 million in Q3 2023.
  • Median Research & Development over the past 5 years was $30.5 million (2023), compared with a mean of $48.5 million.
  • Biggest five-year swings in Research & Development: plummeted 71.59% in 2023 and later soared 45.54% in 2024.
  • Nektar Therapeutics' Research & Development stood at $99.6 million in 2021, then crashed by 65.13% to $34.7 million in 2022, then dropped by 13.81% to $29.9 million in 2023, then decreased by 4.0% to $28.7 million in 2024, then grew by 3.36% to $29.7 million in 2025.
  • The last three reported values for Research & Development were $29.7 million (Q4 2025), $27.3 million (Q3 2025), and $29.9 million (Q2 2025) per Business Quant data.